

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 March 2024 (28.03.2024)



(10) International Publication Number
WO 2024/059934 A1

(51) International Patent Classification:

G01N 33/543 (2006.01) G01N 33/74 (2006.01)
G01N 21/01 (2006.01)

(21) International Application Number:

PCT/CA2023/051227

(22) International Filing Date:

15 September 2023 (15.09.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/408,995 22 September 2022 (22.09.2022) US

(71) Applicant: **HERSTASIS HEALTH FOUNDATION**

[CA/CA]; 325 3rd St., New Westminster, British Columbia
V3L 2R8 (CA).

(72) Inventors: **FINK, Kathryn**; c/o Herstasis Health Founda-
tion, 325 3rd St., New Westminster, British Columbia V3L
2R8 (CA). **THOMPSON, Jennifer**; c/o Herstasis Health
Foundation, 325 3rd St., New Westminster, British Colum-
bia V3L 2R8 (CA). **VANDER ZALM, Jennifer**; c/o Her-
stasis Health Foundation, 325 3rd St., New Westminster,
British Columbia V3L 2R8 (CA).

(74) Agent: **FASKEN MARTINEAU DUMOUNLIN LLP**;
550 Burrard Street, Suite 2900 (Attention: Ling F. Wong),
Vancouver, British Columbia V6C 0A3 (CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

(54) Title: DEVICE, METHOD AND SYSTEM FOR DIAGNOSING, MONITORING AND PREDICTING CHRONIC HEALTH CONDITIONS THROUGH URINE BIOMARKERS




Fig. 1

(57) Abstract: OF THE DISCLOSURE A device, system and method for measuring and monitoring analyte concentrations in urine. The device is a cassette comprising two or more hormone or metabolite fluorometric or colorimetric assays, one of which can quantify urine dilution or concentration relative to population standards. The cassette can accommodate multiple lateral flow and/or dry chemistry assays, wherein the fluorometric or colorimetric results are readable quantitatively by a countertop or handheld reader and the results are normalized by the urine concentration measurement. In preferred embodiments, the analytes relate to symptoms of menopausal transition and have dynamic ranges sufficient to handle the known analyte fluctuations during such transition.

[Continued on next page]

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*